Improving Health, Health Care and Quality of Life
The subpoena requires the production of documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, financial relationships with physicians and joint ventures. The subject matter of this subpoena significantly overlaps with the subject matter of the investigation being conducted by United States Attorney's Office for the Eastern District of Pennsylvania. This subpoena has been issued in connection with a joint civil and criminal investigation.
To the Company's knowledge, no proceedings have been initiated against the Company at this time, although the Company cannot predict whether or when proceedings might be initiated. The Company intends to cooperate with the government's investigation.
Kent Thiry, Chairman & CEO of DaVita stated, "We have worked hard to create and sustain a culture of compliance at DaVita, as well as the policies and systems to support that culture. We look forward to the opportunity to answer whatever questions the government has." Additionally, Mr. Thiry stated, "This process will have no impact on our plans to acquire Gambro Healthcare."
DaVita will be holding a conference call to discuss this matter on March 7, 2005, at 10:30 AM Eastern Time. The dial in number is 800-399-4406. A replay of the conference call will be available on DaVita's official web page, http://www.davita.com/, for the following 30 days.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk,
SOURCE: DaVita Inc.
CONTACT: LeAnne Zumwalt, Investor Relations of DaVita Inc.,
Web site: http://www.davita.com/